MedTrace Logo

Underwater Galvanic Stimulation by 4-Cell Bath on Lymphedema.

NCT06753175 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-18

No results posted yet for this study

Summary

Sixty female patients with lymphedema post mastectomy, aged 30-55 years, will be selected from Minia Oncology Institute. The participants will be randomly distributed into two equal groups:

1. Group A (CDT + Underwater Galvanic Stimulation group):

This group includes 30 patients who will receive underwater galvanic stimulation by 4-cell bath with CDT for 2 months (3times/week) in addition to their medical treatment.
2. Group B (CDT group):

This group includes 30 patients who will receive only CDT for 2 months (3times/week) in addition to their medical treatment.

Conditions

  • Lymphedema

Interventions

DEVICE

underwater galvanic stimulation by 4-cell bath

Underwater Galvanic Stimulation: * Equipment: 4-cell bath * Procedure: Patients will immerse their affected limbs in the 4-cell bath. Electrical stimulation will be applied at a frequency of 15 Hz and intensity of 20 mA for 20 minutes, 3 times per week (Han et al. 2020).

OTHER

Complete Decongestive Therapy (CDT):

Complete Decongestive Therapy (CDT): * Manual Lymphatic Drainage (MLD): 60 minutes per session, 3 days per week. * Compression Therapy: Multilayer bandaging applied after MLD. * Exercise: Specific exercises performed with compression in place. * Skin Care: Routine skin and nail care to prevent infections (Curlett et al. 2020).

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2025-03-15
Completion
2025-05-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06753175 on ClinicalTrials.gov